Multiple Sclerosis

In a promising development in multiple sclerosis research, tolebrutinib delayed the onset of disability progression in patients with nrSPMS.

The bispecific CAR T-cell therapy for treatment of multiple sclerosis is the first to target both CD19 and CD20.

Predicting disease progression is essential to improve the health outcomes of patients with multiple sclerosis.

The findings show that inhibiting connexin 43 significantly improves multiple sclerosis symptoms in an experimental mouse model.

Multiple sclerosis is a debilitating disease affecting many Americans. Pharmacists can help patients control the symptoms that impact their quality of life.

In addition to racial inequities in access to care, socioeconomic challenges are very common for the specialty medications necessary in MS.

This is the largest dataset of pregnancy outcomes for an anti-CD20 therapy in MS, enabling a more comprehensive understanding of ocrelizumab’s safety.

Although this data seems to overwhelmingly suggest that cannabis use has negative impacts for individuals with multiple sclerosis (MS), listening to patients’ reasoning for using it is crucial.

Subcutaneous ocrelizumab can be delivered in approximately 10 minutes and deliver comparable clinical benefit and safety to the IV formulation.

Although resources were scarce for teams at smaller private practices, the pharmacists all agreed that patient care is always the priority.

There has been a general shift toward earlier treatment and less tolerance for clinically silent disease activity.

Although questions remain about ideal treatment strategies, consistent data have shown that patients should be treated early.

The results also showed that the PET scans could show damage to the individual’s brains, which was correlated with disability and fatigue.

Speakers in a presentation discuss a specific patient with MS who experienced urinary complications and the methods used to treat her.

Frexalimab demonstrated a favorable tolerability profile after approximately 1 year of treatment for individuals with relapsing disease.

Ofatumumab (Kesimpta; Novartis) demonstrated a sustained efficacy as a first-line, continuous treatment for patients recently diagnosed and treatment-naïve with relapsing multiple sclerosis.

Ocrelizumab (Ocrevus; Roche) is being investigated as a twice yearly 10-minute subcutaneous injection compared to the intravenous infusion formulation.

The platform is a first-of-its-kind therapeutic approach to promote remyelination among individuals with relapsing/remitting multiple sclerosis.

Monitoring metal ion concentrations and chelation therapy is hypothesized to alleviate symptoms and diseases caused by neuroinflammation.

A subcutaneous injection of ocrelizumab was markedly effective at suppressing brain lesions in patients with multiple sclerosis, according to data from a phase 3 trial.

The FDA is the first regulatory agency globally to approve natalizumab-sztn as a biosimilar for natalizumab.

Long-term data show that early treatment with ofatumumab decreased confirmed disability worsening in nearly all study patients with relapsing multiple sclerosis.

The CBD gummy market is being fueled by the desire for alternative, natural treatment options.

Ublituximab-xiiy from TG Therapeutics Inc is the first anti-CD20 monoclonal antibody approved for individuals with RMS that is administered as a 1-hour infusion after the starting dose.

With the advent of disease-modifying therapies, the life span of patients with multiple sclerosis has increased dramatically.

Ozanimod is an oral, sphinogosine 1-phosphate (S1P) receptor modulator that binds with high affinity to S1P receptors 1 and 5.

Investigational targeted B-cell therapy demonstrates superior efficacy compared with teriflunomide, a commonly prescribed treatment for MS.

Researchers highlight how a lack of access to medications used to treat multiple sclerosis, migraines, and epilepsy, but not proven safe for pregnancy, threatens child-bearing aged women who live with these conditions.

After 4 years of treatment with ofatumumab, 78.8% of patients with relapsing forms of multiple sclerosis who continuously received ofatumumab achieved NEDA-3 compared to 51.8% of those who switched from teriflunomide to ofatumumab.

Jazz Pharmaceuticals announced top-line results from the phase 3 RELEASE MSS1 trial, evaluating nabiximols oromucosal spray in individuals with multiple sclerosis.